Vai al contenuto| Home page|

   Ti trovi in: HOME »Programmi, progetti e risultati »I progetti »PRIN - Programmi di ricerca di Rilevante Interesse Nazionale»Programma di ricerca
INIZIO_TESTO_DA_INDICIZZARE

RESEARCH PROGRAM

italiano - inglese
Similar research programs:
Scientific and education field classification
International Patent Classification
  • HUMAN NECESSITIES
    • MEDICAL OR VETERINARY SCIENCE; HYGIENE
      • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]
      • THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
Geographical classification
Keywords
MEDICINAL CHEMISTRY; CARDIOVASCULAR DRUGS; ANTIHYPERTENSIVE DRUGS; ANTIARRHYTHMIC DRUGS; ANTI-ATHEROSCLEROTIC AGENTS; ANTI-THROMBIOTIC AGENTS; ANTIANGINAL DRUGS; HYPOLIPIDEMIC DRUGS; ANTIPLATELET DRUGS

DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NEW CARDIOVASCULAR DRUGS

Università degli Studi di Bari
Abstract
The aim of this research project is to study compounds active on the cardiovascular system. The pharmacological classes that will be the object of this research are:
a) antihypertensive drugs acting via interaction with angiothensin receptors and NO release;
b) antiarrhythmic drugs acting on cardiac sodium channels and characterized by a reduced incidence of adverse effects;
c) antiatherosclerotic and anti-thrombotic agents (lipid-regulating agents, platelet aggregation inhibitors, radical scavengers, and inhibitors of myocyte proliferation) mainly targeted to:
c.1 interaction with different PPAR receptors that seem to regulate several cardiovascular disorders;
c.2 inhibition of platelet aggregation and radical production that seem to cause endothelial damages underlying atherosclerosis;
c.3 acyl-CoA: cholesterol acyl transferase (ACAT) inhibition as an alternative treatment for hypercholesterolemia;
d) anti-ischemic drugs acting through
d.1 NO release;
d.2 opening of mitochondrial ATP-sensitive potassium channels (mito-KATP);
d.3 interaction with specific adenosine receptor subtypes.

Principal Investigator
Vincenzo TORTORELLA Università degli Studi di BARI
Research Objectives
Taken together, cardiovascular diseases are the leading cause of death in industrialized countries. Various pharmacological approaches can be pursued for the treatment of these pathologies and, among them, the lowering of hypertension, the control of the causative factors of platelet aggregation at the vascular level and the regulation of the disorders underlying atherosclerosis (dislipidemia and endothelial damage caused by mechanical or chemical insults) are particularly important. In addition, within the class of the cardiovascular drugs, compounds able to regulate cardiac frequency have important applications.
The present project aims to gain new insight into the mode of action of compounds active on the cardiovascular system. Additionally it aims to further optimize the activity/side effects ratio of available drugs and to discover entirely new leads. The national team submitting this proposal is composed of five local research groups (Bari, Chieti, Milano, Pisa, and Torino). The staff engaged in the research is made up of 15 full professors, 7 associate professors and 11 university researchers. Many doctoral and post-doctoral students as well as holders of research grants and fellowships will also be collaborating with the permanent staff. The interdisciplinary nature of this research project requires chemical and biological expertise within the group. It has been possible to satisfy this demand in that some pharmacologists have decided to participate in the >>>

Timescale
24 months
National and international background
The national program submitted herein foresees the study of drugs with potential for use in the treatment of cardiovascular pathologies. The subject is of great importance in modern clinical practice, due not only to the frequency of cardiovascular diseases but also for the seriousness of their effects on health. An indication of the level of interest in this field is given by the high percentage of the new chemical entities registered for the treatment of cardiovascular disorders, in relation to the total number of new drugs brought onto the market over the last few years.
During the last few decades, numerous studies have been conducted with the aim of gaining insight into the factors contributing to the development of pathologies such as cerebral stroke and myocardial infarction. Although some of these risk factors (e.g. age, gender) are not amenable to modification, others such as hypertension, dyslipidemia, obesity and diabetes can be modified or controlled by the use of appropriate medication and/or a change in life style. The simultaneous presence of more than one risk factor considerably increases the probability of developing cardiovascular problems, and makes the use of safe and selective drugs an absolute necessity.
At the international level, the four classes of drugs that are the object of this program have been extensively investigated. The members of the research groups participating in the present project are all recognized national experts >>>